Pharming Group N.V. Q3 2024 Financial Summary
Business Context and Reporting Period
This Form 6-K filing, dated October 24, 2024, presents the preliminary, unaudited financial results for Pharming Group N.V. for the third quarter and first nine months ended September 30, 2024. The company is a global biopharmaceutical firm focused on rare diseases, primarily commercializing RUCONEST® (for hereditary angioedema) and Joenja® (leniolisib, for APDS).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $74.8 million | $66.7 million | $204.5 million | $164.1 million |
| Gross Profit | $68.0 million | $58.4 million | $181.3 million | $146.0 million |
| Operating Profit (Loss) | $4.1 million | $1.9 million | ($15.3) million | ($6.5) million |
| Net Profit (Loss) | ($1.0) million | $3.5 million | ($14.7) million | ($7.4) million |
| Cash & Marketable Securities | $173.3 million | N/A | $173.3 million | $215.0 million (Dec 2023) |
| Operating Cash Flow | $9.7 million | $3.5 million | ($11.1) million | ($28.9) million |
Revenue Breakdown (Q3 2024): RUCONEST® generated $63.6 million (6% YoY growth), while Joenja® generated $11.2 million (72% YoY growth). The U.S. market accounted for 97% of RUCONEST® revenue and the majority of Joenja® revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% in Q3 and 25% for the first nine months, driven by volume growth in both core products and a U.S. price increase for RUCONEST® aligned with CPI.
- Profitability: The company achieved a positive operating profit of $4.1 million in Q3, compared to $1.9 million in Q3 2023. This was driven by higher gross profit offset by increased operating expenses ($64.7 million vs. $56.8 million) due to investments in Joenja® expansion and R&D.
- Net Loss Drivers: Despite operating profit, Q3 net loss was $1.0 million (vs. $3.5 million profit in Q3 2023) primarily due to unfavorable EUR/USD exchange rate impacts ($1.5 million loss) and higher interest expenses following a convertible bond issuance.
- One-Time Items: The 9M 2023 results included a $21.1 million gain from the sale of a Priority Review Voucher (PRV) and $10.5 million in milestone payments, which are not present in 2024, distorting year-over-year operating comparisons.
Guidance, Outlook, and Management Commentary
- 2024 Guidance: Management reaffirmed full-year 2024 revenue guidance of $280 million to $295 million (14% - 20% growth).
- CEO Transition: CEO Sijmen de Vries announced he will not seek reappointment at the May 2025 Annual General Meeting after a 16-year tenure. A global executive search firm has been engaged to find a successor.
- Product Pipeline:
- Joenja®: Received U.K. marketing authorization in September 2024; reimbursement evaluation by NICE is ongoing. A Phase II trial for leniolisib in broader primary immunodeficiencies (PIDs) began in October 2024, targeting a potential five-fold increase in commercial opportunity.
- RUCONEST®: Continued strong performance with approximately 100 new patient enrollments in the U.S. during Q3.
- Liquidity: Cash and marketable securities increased to $173.3 million in Q3 2024 from $161.8 million in Q2 2024, supported by positive operating cash flows of $9.7 million.
Investor Verification Checklist
- CEO Succession Plan: Monitor the timeline and criteria for the appointment of the new CEO to ensure strategic continuity.
- U.K. Reimbursement: Track the outcome of the NICE evaluation for Joenja® in the U.K., which is critical for European expansion.
- Convertible Bond Impact: Verify the ongoing impact of interest expenses and foreign exchange fluctuations on net income, given the recent bond issuance and EUR/USD volatility.
- Phase II Trial Progress: Confirm enrollment rates and preliminary safety data for the new leniolisib PID trial to validate the expanded market thesis.
- Operating Expense Trajectory: Assess whether operating expenses will stabilize or continue to rise as the company invests in global launches and R&D.